[Federal Register Volume 61, Number 11 (Wednesday, January 17, 1996)]
[Notices]
[Pages 1191-1192]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-487]
-----------------------------------------------------------------------
[[Page 1192]]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Vaccine Advisory Committee (NVAC), Subcommittee on
Vaccine Safety and the Advisory Commission on Childhood Vaccines (ACCV)
Subcommittee on Vaccine Safety, Subcommittee on Immunization Coverage,
and Subcommittee on Future Vaccines: Meetings
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following Federal advisory committee
meetings.
Name: National Vaccine Advisory Committee (NVAC).
Times and Dates: 8:30 a.m.-2:30 p.m., January 22, 1995. 8:30
a.m.-1 p.m., January 23, 1996.
Place: Savoy Suites Georgetown, 2505 Wisconsin Avenue, NW,
Washington, DC 20007.
Status: Open to the public, limited only by the space available.
Purpose: The Committee shall advise and make recommendations tot
he Director of the National Vaccine Program on matters related to
the Program responsibilities.
Matters to be Discussed: The Committee will receive an update on
the National Vaccine Program Office and National Vaccine Advisory
Committee operations; update on the Interagency Task Force on
Vaccine Safety and funding for acting surveillance; update on
immunization deliver: insights from recent research on vaccine
coverage and a report on the new Women, Infants, and Childrens
demonstration projects; update on vaccine program funding; update
from the subcommittee on immunization coverage; proposal for a
potential solution to the problem of an increasing menu of pediatric
vaccines; defining a vaccine manufacturer/government partnership;
update on adult immunization strategies and priorities; report on
the influenza pandemic plan; role of the NVAC in fostering the
pandemic influenza plan; update on the future vaccines subcommittee;
presentation on the presence of reverse transcriptase activity in
vaccine products; status of the Advisory Committee on Immunization
Practices reevaluation of polio immunization recommendations and
adolescent immunization; update on the injury compensation system;
an update on USAID; and an information presentation on recent
immunization compensation cases impacting immunization.
Name: Subcommittee on Vaccine Safety and the Advisory Commission
on Childhood Vaccines Subcommittee on Vaccine Safety.
Time and Date: 2:30 p.m.-5 p.m., January 22, 1996
Place: Savoy Suites Georgetown, 2505 Wisconsin Avenue, NW,
Washington, DC 20007.
Status: Open to the public, limited only by the space available.
Purpose: This joint ACCV/NVAC subcommittee will review issues
relevant to vaccine safety and adverse reactions to vaccines.
Matters to be Discussed: The Subcommittee will discuss the
Institute of Medicine vaccine safety forum and summary of planned
workshops; the task force on safer childhood vaccines; and the
charge of the Subcommittees.
Name: Subcommittee on Immunization Coverage.
Time and Date: 2:30 p.m.-5 p.m., January 22, 1996
Place: Savoy Suites Georgetown, 2505 Wisconsin Avenue, NW,
Washington, DC 20007.
Status: Open to the public, limited only by the space available.
Purpose: The Subcommittee on Immunization Coverage will identify
strategies and policy options by which to further improve the levels
of immunization coverage.
Matters to be Discussed: The Subcommittee will discuss
determinants of under vaccination in preschool children; national,
State, and local immunization coverage levels; current interventions
for immunization and the future health environment.
Name: Subcommittee on Future Vaccines.
Time and Date: 2:30 p.m.-5 p.m., January 22, 1996.
Place: Savoy Suites Georgetown, 2505 Wisconsin Avenue, NW,
Washington, DC 20007.
Status: Open to the public, limited only by the space available.
Purpose: The Subcommittee on Future Vaccines will develop policy
options and guide national activities which will lead to accelerated
development, licensure, and best use of new vaccines in the simplest
possible immunization schedules.
Matters to be Discussed: The Subcommittee will review and
discuss the terms of reference for the Subcommittee; identify the
matrix of interactions and partnerships, via specific case studies;
describe the process of priority-setting by each of the members of
the vaccine research and development community, and define barriers
to new vaccine development.
Agenda items for each meeting are subject to change as
priorities dictate.
The shutdown of the Federal Government prevented meeting the 15-
day publication requirement.
Contact Person for More Information: Gloria A. Kovach, Committee
Management Specialist, National Vaccine Program Office, CDC, 1600
Clifton Road, NE, M/S A20, Atlanta, Georgia 30333, telephon 404/639-
3851.
Dated: January 10, 1996.
Carolyn J. Russell,
Director, Management Analysis and Services Office Centers for Disease
Control and Prevention (CDC).
[FR Doc. 96-487 Filed 1-11-96; 8:45 am]
BILLING CODE 4163-18-M